Shinichiro Motohashi

Chuo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 76 publications

Distinct thymic pDC populations promote tumor immune tolerance through complementary mechanisms.

Distinct thymic pDC populations promote tumor immune tolerance through complementary mechanisms.

Journal: Science advances

Published: July 23, 2026

Extending the residence period of allogeneic iPSC-derived invariant natural killer T cells in humanized mice by editing HLA class I expression.

Extending the residence period of allogeneic iPSC-derived invariant natural killer T cells in humanized mice by editing HLA class I expression.

Journal: Frontiers in cell and developmental biology

Published: April 30, 2026

CD69 regulates the tissue dynamics of epigenetically imprinted memory CD4+ T cells.

CD69 regulates the tissue dynamics of epigenetically imprinted memory CD4+ T cells.

Journal: Science advances

Published: April 08, 2026

Psychological Stress Promotes Tumor Growth in Hepatocellular Carcinoma Models Through Myeloid Signaling.

Psychological Stress Promotes Tumor Growth in Hepatocellular Carcinoma Models Through Myeloid Signaling.

Journal: Cancer science

Published: February 15, 2026

Hepatic leukemia factor directs tissue residency of proinflammatory memory CD4+ T cells.

Hepatic leukemia factor directs tissue residency of proinflammatory memory CD4+ T cells.

Journal: Science (New York, N.Y.)

Published: December 11, 2025

Lipolysis-microlipophagy cascade regulated by adipose triglyceride lipase drives pathogenic adaptive type 2 immunity.

Lipolysis-microlipophagy cascade regulated by adipose triglyceride lipase drives pathogenic adaptive type 2 immunity.

Journal: Science immunology

Published: October 24, 2025

Hyodeoxycholic acid suppresses hepatic steatosis in a PPARα-dependent manner via distinct GLP-1- and iNKT cell-mediated pathways.

Hyodeoxycholic acid suppresses hepatic steatosis in a PPARα-dependent manner via distinct GLP-1- and iNKT cell-mediated pathways.

Journal: Cell reports

Published: October 02, 2025

A phase I clinical trial to evaluate the tolerability and safety of an allogeneic iPSC-derived iNKT cell and α-GalCer-pulsed autologous DC combination therapy for patients with recurrent and advanced head and neck cancer: A study protocol.

A phase I clinical trial to evaluate the tolerability and safety of an allogeneic iPSC-derived iNKT cell and α-GalCer-pulsed autologous DC combination therapy for patients with recurrent and advanced head and neck cancer: A study protocol.

Journal: PloS one

Published: September 19, 2025

MGMT Promoter Methylation in Glioblastoma Stem Cells: Stability During Differentiation and Comparison With Surgically-resected Tumors.

MGMT Promoter Methylation in Glioblastoma Stem Cells: Stability During Differentiation and Comparison With Surgically-resected Tumors.

Journal: Anticancer research

Published: August 04, 2025

Preclinical efficacy of combination therapy with allogeneic induced pluripotent stem cell-derived invariant natural killer T and α-galactosylceramide-pulsed antigen-presenting cells.

Preclinical efficacy of combination therapy with allogeneic induced pluripotent stem cell-derived invariant natural killer T and α-galactosylceramide-pulsed antigen-presenting cells.

Journal: Stem cell research & therapy

Published: July 12, 2025

Allogeneic iPSC-derived iNKT cells in recurrent head and neck cancer: a phase 1 trial.

Allogeneic iPSC-derived iNKT cells in recurrent head and neck cancer: a phase 1 trial.

Journal: Nature communications

Published: July 01, 2025

LSD1 inhibitor, TAS1440, disrupts INSM1-LSD1 complex activating tumor-suppressive pathways via transcriptional reprogramming in neuroendocrine SCLC.

LSD1 inhibitor, TAS1440, disrupts INSM1-LSD1 complex activating tumor-suppressive pathways via transcriptional reprogramming in neuroendocrine SCLC.

Journal: Nature communications

Published: January 02, 2025

Showing 1-12 of 76

Last Updated: 09/26/2026